| Previous close | 0.8600 |
| Open | 0.8600 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 17.50 |
| Expiry date | 2024-11-15 |
| Day's range | 0.8500 - 0.8600 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Business WireBausch + Lomb Announces Presentation of New Scientific Data and Evaluations Featuring Consumer, Vision Care and Pharmaceutical Products at Optometry’s Meeting®
VAUGHAN, Ontario, May 28, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 12 ePosters during the American Optometric Association (AOA) Optometry’s Meeting ePoster Session, taking place virtually May 29-30, 2024. The company will also have three live presentations and host nine education events during the in-person meeting, taking place in Nashville June 19-22, 2024.
Business WireBausch + Lomb Receives Health Canada Approval for enVista® Envy™* Full Visual Range Intraocular Lens
VAUGHAN, Ontario, May 28, 2024--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Health Canada has approved the enVista® Envy™* full visual range intraocular lens (IOL). This is the first global regulatory approval of the new lens, which offers a full range of vision with excellent dysphotopsia tolerance on the widely used enVista IOL platform.
Simply Wall St.Bausch + Lomb First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Bausch + Lomb ( NYSE:BLCO ) First Quarter 2024 Results Key Financial Results Revenue: US$1.10b (up 18% from 1Q 2023...
